Clinical use of adiponectin as a marker of metabolic dysregulation

Kieren Mather, Ronald B. Goldberg

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Adiponectin concentrations exhibit strong cross-sectional relationships with obesity, inflammation, and diabetes. Adiponectin concentrations have been extensively evaluated as epidemiologic markers of diabetes and cardiovascular disease risk. In the present review we will provide an overview of these epidemiologic relationships as the backdrop for an evaluation of the clinical applications of adiponectin measurements. These include using adiponectin as an indicator of need for preventive or therapeutic intervention, as a predictor of response to therapy, and as a marker of therapeutic effectiveness. These efforts are laying the groundwork for the transition of adiponectin measurements from the laboratory to the clinic.

Original languageEnglish (US)
Pages (from-to)107-117
Number of pages11
JournalBest Practice and Research: Clinical Endocrinology and Metabolism
Volume28
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Adiponectin
Cardiovascular Diseases
Therapeutics
Obesity
Inflammation

Keywords

  • adiponectin
  • inflammation
  • insulin resistance
  • obesity
  • prediction
  • therapy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Clinical use of adiponectin as a marker of metabolic dysregulation. / Mather, Kieren; Goldberg, Ronald B.

In: Best Practice and Research: Clinical Endocrinology and Metabolism, Vol. 28, No. 1, 01.01.2014, p. 107-117.

Research output: Contribution to journalArticle

@article{bc0810e0d5db4330b9485c19d1c73367,
title = "Clinical use of adiponectin as a marker of metabolic dysregulation",
abstract = "Adiponectin concentrations exhibit strong cross-sectional relationships with obesity, inflammation, and diabetes. Adiponectin concentrations have been extensively evaluated as epidemiologic markers of diabetes and cardiovascular disease risk. In the present review we will provide an overview of these epidemiologic relationships as the backdrop for an evaluation of the clinical applications of adiponectin measurements. These include using adiponectin as an indicator of need for preventive or therapeutic intervention, as a predictor of response to therapy, and as a marker of therapeutic effectiveness. These efforts are laying the groundwork for the transition of adiponectin measurements from the laboratory to the clinic.",
keywords = "adiponectin, inflammation, insulin resistance, obesity, prediction, therapy",
author = "Kieren Mather and Goldberg, {Ronald B.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.beem.2013.06.008",
language = "English (US)",
volume = "28",
pages = "107--117",
journal = "Best Practice and Research in Clinical Endocrinology and Metabolism",
issn = "1521-690X",
publisher = "Bailliere Tindall Ltd",
number = "1",

}

TY - JOUR

T1 - Clinical use of adiponectin as a marker of metabolic dysregulation

AU - Mather, Kieren

AU - Goldberg, Ronald B.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Adiponectin concentrations exhibit strong cross-sectional relationships with obesity, inflammation, and diabetes. Adiponectin concentrations have been extensively evaluated as epidemiologic markers of diabetes and cardiovascular disease risk. In the present review we will provide an overview of these epidemiologic relationships as the backdrop for an evaluation of the clinical applications of adiponectin measurements. These include using adiponectin as an indicator of need for preventive or therapeutic intervention, as a predictor of response to therapy, and as a marker of therapeutic effectiveness. These efforts are laying the groundwork for the transition of adiponectin measurements from the laboratory to the clinic.

AB - Adiponectin concentrations exhibit strong cross-sectional relationships with obesity, inflammation, and diabetes. Adiponectin concentrations have been extensively evaluated as epidemiologic markers of diabetes and cardiovascular disease risk. In the present review we will provide an overview of these epidemiologic relationships as the backdrop for an evaluation of the clinical applications of adiponectin measurements. These include using adiponectin as an indicator of need for preventive or therapeutic intervention, as a predictor of response to therapy, and as a marker of therapeutic effectiveness. These efforts are laying the groundwork for the transition of adiponectin measurements from the laboratory to the clinic.

KW - adiponectin

KW - inflammation

KW - insulin resistance

KW - obesity

KW - prediction

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=85047686974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047686974&partnerID=8YFLogxK

U2 - 10.1016/j.beem.2013.06.008

DO - 10.1016/j.beem.2013.06.008

M3 - Article

VL - 28

SP - 107

EP - 117

JO - Best Practice and Research in Clinical Endocrinology and Metabolism

JF - Best Practice and Research in Clinical Endocrinology and Metabolism

SN - 1521-690X

IS - 1

ER -